Melanoma Research Victoria

Journal of Cancer Survivorship The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors Julia Lai-Kwon, Chloe Khoo, Serigne Lo, Donna Milne, Mustafa Mohamed, Jeanette Raleigh, Kortnye Smith, Karolina Lisy, Shahneen Sandhu, Michael Jefford Original Research First Online: 04 June 2019 (https://doi.org/10.1007/s11764-019-00770-0) The lancet Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial […]

Read the full story

Source: MDLinx, July 2019 Researchers conducted this retrospective, matched cohort study to quantify the incidence of melanoma and nonmelanoma skin cancer (NMSC) in Korean vitiligo patients and compare it with their matched non-vitiligo controls. The study sample consisted of 131,245 incident vitiligo cases and 2,624,900 age and sex-matched (1:20) controls at index date, who were […]

Read the full story

Source: ScienceDaily, July 2019 Almost 300,000 people worldwide develop malignant melanoma each year. The disease is the most serious form of skin cancer and the number of cases reported annually is increasing, making skin cancer one of Sweden’s most common forms of cancer. A research team at Lund University in Sweden has studied a protein […]

Read the full story

Source: OncLive, July 2019 Transcript: Jeffrey S. Weber, MD, PhD: Melanoma is the deadliest form of skin cancer, but unprecedented advances in immunotherapy and targeted agents have led to safer and more effective ways to treat this disease. Today I’m joined by a panel of experts in melanoma to delve into the latest studies, including the […]

Read the full story